- Home
- REPL vs NUS Comparison
REPL vs NUS Comparison
Compare REPL & NUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- NUS
- Stock Information
- Founded
- REPL 2015
- NUS 1984
- Country
- REPL United States
- NUS United States
- Employees
- REPL N/A
- NUS N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- NUS Other Pharmaceuticals
- Sector
- REPL Health Care
- NUS Health Care
- Exchange
- REPL Nasdaq
- NUS Nasdaq
- Market Cap
- REPL 547.0M
- NUS 603.4M
- IPO Year
- REPL 2018
- NUS 1996
- Fundamental
- Price
- REPL $10.07
- NUS $10.68
- Analyst Decision
- REPL Buy
- NUS Hold
- Analyst Count
- REPL 9
- NUS 2
- Target Price
- REPL $10.88
- NUS $6.88
- AVG Volume (30 Days)
- REPL 8.8M
- NUS 408.3K
- Earning Date
- REPL 11-07-2025
- NUS 11-06-2025
- Dividend Yield
- REPL N/A
- NUS 2.25%
- EPS Growth
- REPL N/A
- NUS N/A
- EPS
- REPL N/A
- NUS 2.03
- Revenue
- REPL N/A
- NUS $1,626,325,000.00
- Revenue This Year
- REPL N/A
- NUS N/A
- Revenue Next Year
- REPL N/A
- NUS $0.98
- P/E Ratio
- REPL N/A
- NUS $5.25
- Revenue Growth
- REPL N/A
- NUS N/A
- 52 Week Low
- REPL $2.68
- NUS $5.32
- 52 Week High
- REPL $17.00
- NUS $14.62
- Technical
- Relative Strength Index (RSI)
- REPL 75.32
- NUS 41.68
- Support Level
- REPL $7.69
- NUS $10.49
- Resistance Level
- REPL $10.85
- NUS $11.28
- Average True Range (ATR)
- REPL 0.67
- NUS 0.26
- MACD
- REPL 0.48
- NUS -0.00
- Stochastic Oscillator
- REPL 88.10
- NUS 37.82
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.